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Abstract
Introduction: Indirect immunofluorescence (IIF) employing ethanol-fixed neutrophils (ethN) is still the method of
choice for assessing antineutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitides (AAV). However,
conventional fluorescence microscopy is subjective and prone to high variability. The objective of this study was to
evaluate novel pattern recognition algorithms for the standardized automated interpretation of ANCA patterns.
Methods: Seventy ANCA-positive samples (20 antimyeloperoxidase ANCA, 50 antiproteinase3 ANCA) and 100
controls from healthy individuals analyzed on ethN and formalin-fixed neutrophils (formN) by IIF were used as a
‘training set’ for the development of pattern recognition algorithms. Sera from 342 patients (’test set’) with AAV
and other systemic rheumatic and infectious diseases were tested for ANCA patterns using the novel pattern
recognition algorithms and conventional fluorescence microscopy.
Results: Interpretation software employing pattern recognition algorithms was developed enabling positive/
negative discrimination and classification of cytoplasmic ANCA (C-ANCA) and perinuclear ANCA (P-ANCA).
Comparison of visual reading of the ‘test set’ samples with automated interpretation revealed Cohen’s kappa ()
values of 0.955 on ethN and 0.929 on formN for positive/negative discrimination. Analysis of the ‘test set’ with
regard to the discrimination between C-ANCA and P-ANCA patterns showed a high agreement for ethN ( =
0.746) and formN ( = 0.847). There was no significant difference between visual and automated interpretation
regarding positive/negative discrimination on ethN and formN, as well as ANCA pattern recognition (P > 0.05,
respectively).
Conclusions: Pattern recognition algorithms can assist in the automated interpretation of ANCA IIF. Automated
reading of ethN and formN IIF patterns demonstrated high consistency with visual ANCA assessment.
Introduction
Antineutrophil cytoplasmic antibodies (ANCA)-asso-
ciated systemic small vessel vasculitis (AAV) comprising
granulomatosis with polyangiitis (GPA, previously
known as Wegener’s granulomatosis, microscopic poly-
angiitis (MPA), and eosinophilic granulomatosis with
polyangiitis (EGPA), previously known as Churg-Strauss
syndrome, is a group of related autoimmune disorders
characterized by microvascular inflammation, tissue
necrosis, and circulating ANCA [1-6]. According to the
recommendations for ANCA diagnostics, positive find-
ings of standard screening tests by indirect immuno-
fluorescence (IIF) on ethanol-fixed neutrophils (ethN)
need to be confirmed with antigen-specific enzyme-
linked immunosorbent assays (ELISAs) [4]. Dependent
on ethN IIF pattern, ANCA can be subclassified into
cytoplasmic ANCA (C-ANCA) and perinuclear ANCA
(P-ANCA) patterns. Non-C/P-ANCA patterns are
usually reported as atypical ANCA, which have been
found in particular in patients with inflammatory bowel
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disease [7-9]. The majority of C-ANCA recognizes pro-
teinase 3 (PR3) and a positive C-ANCA pattern con-
firmed by an anti-PR3-ANCA ELISA is pathognomonic
for GPA [1,3]. In contrast, the main autoantigenic target
of P-ANCA is myeloperoxidase (MPO) and such ANCA
have been demonstrated in patients with MPA, EGPA
and less frequently in Goodpasture’s syndrome patients.
Furthermore, the titer of both anti-PR3-ANCA and anti-
MPO-ANCA is strongly associated with the active and
inactive state of GPA and MPA, respectively. Due to the
observations that anti-MPO-ANCA and antinuclear
antibodies (ANAs) may demonstrate similar IIF patterns
on ethN, IIF on formalin-fixed neutrophils (formN) is
employed for their discrimination [10].
Pattern interpretation of ANCA is characterized by
human bias and high variability due to methodological
issues such as differing fixation protocols for neutrophils
and fluorescence microscopy components (for example,
lamps, filters, objectives) [11]. Remarkably, computer-
based image analysis of IIF patterns by pattern recogni-
tion algorithms has recently been successfully applied
for automated analysis of ANA by HEp-2 cell-based
assays [12-14], of dsDNA antibodies by Crithidia cell-
based assays and of ANCA by neutrophil cell-based
assays [15,16]. However, the study of Melegari et al. [16]
published as a review covered a small number of sam-
ples and only positive/negative discrimination between
manual and automated ANCA pattern interpretation.
Interestingly, Boomsma et al. reported earlier an IIF
method for the quantitative image analysis of anti-PR3
antibody positive GPA patients [17]. The study did not
reveal major differences between quantitative image ana-
lysis and the other techniques including ELISA and
titration by manual IIF in their capacity to predict
relapses of disease activity. However, no comprehensive
approach using pattern recognition algorithms for auto-
mated ANCA pattern interpretation like in the present
study has been reported so far. Furthermore, we provide
for the first time variability data of an automated ANCA
IIF pattern interpretation in the present study. In parti-
cular, a novel pattern recognition algorithm software
module for ANCA pattern analysis has been established
on the automated reading system AKLIDES™ and was
compared to conventional routine interpretation of
ANCA by IIF on ethN and formN.
Materials and methods
Patients
Seventy ANCA positive samples with distinct ANCA
specificities (20 anti-MPO-ANCA, 7 males, 13 females,
median age 68 years, range 57 to 74 years and 50 anti-
PR3-ANCA positives, 32 males, 18 females, median age
63 years, range 17 to 83 years) and sera from 100 age-
and sex-matched healthy volunteers were used as a
‘training set’ for the development of a ANCA pattern
recognition algorithm module for the automated
AKLIDES™ system. Sera were tested for MPO or PR3
ANCA by ELISA and line immunodot assay (LIA) (GA
Generic Assays GmbH, Dahlewitz/Berlin, Germany).
As the ‘test set’, 342 serum samples from patients with
AAV, other systemic rheumatic and infectious diseases
as controls and from healthy individuals were used
(Table 1). Patients were diagnosed based on typical dis-
ease history, characteristic clinical findings, and con-
firmed clinical histology according to the criteria of the
1992 Chapel Hill Consensus Conference, the consensus
statement of 1999 and the 1990 American College of
Rheumatology [2,4,18]. Serum samples were obtained
from patients with a confirmed clinical diagnosis of
GPA, EGPA or MPA irrespective of serology (that is,
presence of ANCA was not used as a diagnostic criter-
ion). All serum samples were taken at the time of diag-
nosis. Serum samples from patients with systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA) were
also used as disease controls. Disease extent was
assessed using the Disease Extent Index (DEI) and dis-
ease activity using the Birmingham Vasculitis Activity
Score (BVAS) at the time point when the sera were col-
lected from the GPA, EGPA and MPA patients [19,20].
In total, 51 sera from patients with infectious disease
(Treponema pallidum (n = 1), cytomegalovirus (n = 25),
rubella virus (n = 5), Toxoplasma gondii (n = 16), hepa-
titis C (n = 1), Eppstein-Barr virus (n = 3) were included
as disease controls in the test set. Furthermore, sera
from 44 age- and sex-matched healthy volunteers were
tested as control samples in the test set.
The study received approval from the ethical commit-
tee of the Technical University of Dresden
(EK226112006) and fulfilled the ethical guidelines of the
Table 1 Patient characteristics of the ‘test set’ comprising
342 serum samples.
Diagnosis n (%) age gender f/m
GPA 59 (17.3) 21 - 81 36/23
EGPA 40 (11.7) 21 - 70 20/20
MPA 20 (5.8) 17 - 80 13/7
SLE 40 (11.7) 20 - 72 31/9
RA 30 (8.8) 40 - 81 23/7
RA and rheumatoid vasculitis 10 (2.9) 44 - 67 5/5
Cryoglobulinaemic vasculitis 10 (2.9) 43 - 78 7/3
Systemic sclerosis 38 (11.1) 35 - 84 27/11
Infectious diseases 51 (14.9) 5 - 86 46/5
Healthy controls 44 (12.9) 23 - 71 28/16
Patients with GPA consist of cases with generalized and localized GPA
demonstrating inactive as well as active disease. Patients with EGPA cover
cases with active and inactive disease. EGPA, eosinophilic granulomatosis with
polyangiitis (Churg-Strauss Syndrome); GPA, granulomatosis with polyangiitis
(Wegener’s); f, female; m, male; MPA, microscopic polyangiitis; RA, rheumatoid
arthritis; SLE, systemic lupus erythematosus.
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most recent declaration of Helsinki. Written informed
consent was obtained from each patient.
Indirect immunofluorescence (IIF)
Employing IIF, ANCA were detected by running patient
samples on ethN and formN according to the recom-
mendations of the manufacturer (GA Generic Assays
GmbH, Dahlewitz/Berlin, Germany). Briefly, fixed
human neutrophils were incubated in a moist chamber
at room temperature (RT) for 30 minutes with 25 μl of
serum diluted 1:20. After washing, immune complexes
were detected by incubating the samples with fluores-
cein isothiocyanate (FITC)-conjugated goat anti-human
IgG for 30 minutes at RT. Samples were subsequently
washed, embedded with a mounting medium containing
4’,6-diamidino-2-phenylindol (DAPI) for nuclear stain-
ing, and analysed automatically by the novel ANCA pat-
tern recognition algorithm module of AKLIDES™
(Medipan GmbH, Dahlewitz/Berlin, Germany) followed
by manual interpretation with a routine fluorescence
microscope (Carl Zeiss AG, Jena, Germany). To mini-
mize subjectivity, manual reading was carried out always
by two investigators (IK, TBr, TB, KG and EC).
AKLIDES™ - technical system and pattern recognition
algorithm software
The concept of the fully automated interpretation system
AKLIDES™ for evaluation of ANCA IIF patterns is based
on novel mathematical software algorithms for pattern
recognition [12,21]. Neutrophils were assessed automati-
cally using a motorized inverse microscope (IX81, Olym-
pus Corporation, Tokyo, Japan) with a motorized
scanning stage (IM120, Märzhäuser, Wetzlar, Germany);
400 nm and 490 nm light-emitting diodes (LED) (Preci-
sExcite, CoolLED, Andover, UK), and a charge-coupled
device grey-scale camera (DX4, Kappa, Gleichen, Ger-
many). The interpretation system is controlled by the
AKLIDES™ software consisting of modules for device
and autofocus control, image analysis, and pattern recog-
nition algorithms. The novel autofocus based on Hara-
lick’s image characterization of objects through grey-scale
transition using DAPI as fluorescent dye for focusing,
quality evaluation, and object recognition.
Two-dimensional images were acquired using an
objective with 40-fold magnification (Olympus semi-
apochromat LUCPLFLN 40X, 0.60 NA, W.D. 2.7-4.0
mm). Fluorescence detection was performed using LED
excitation with appropriate multiband filter for the
DAPI and FITC dyes (DA/FI-A, Semrock, Rochester,
USA). Single DAPI and FITC image were serially cap-
tured and stored in lossless compressed Tagged Image
File (TIF) format.
To eliminate artifacts, an additional qualitative image
analysis was performed by dividing the image content
into tiles of equal size with subsequent calculation of
tile sharpness and homogeneity. Object segmentation
was conducted by histogram-based threshold algorithm
followed by watershed transformation [21]. Cell aggre-
gates were excluded by analyzing convexity of objects.
Segmented granulocytes were characterized by regional,
topological, and texture/surface descriptors by employ-
ing DAPI and FITC image data (Figure 1a). A minimum
of 20 granulocytes were counted at each slide.
Statistical analysis
Fisher’s exact test was used to check the differences
between the two classification systems. To test for the
strength of agreement, inter-rater agreement statistics
was conducted. McNemar test was performed to check
the difference for paired proportions. P values of less
than 0.05 were considered as or to be significant. Calcu-
lations were performed by using MedCalc™ statistical
software (MedCalc, Mariakerke, Belgium).
Results
Development of ANCA pattern recognition algorithms on
AKLIDES™
For the automated interpretation of ANCA IIF patterns
and evaluation of its diagnostic performance, a novel
ANCA pattern recognition algorithm software module
was established for the multicolor-fluorescence reading
system AKLIDES™ employing topographical, texture,
boundary, and regional descriptors for image analysis.
Both ANCA pattern detection and description follow a
two-step approach. At first, DAPI staining was used for
image focusing, checking of scene quality, and neutro-
phil identification. Afterwards, signal intensity and pat-
tern classification for appropriate neutrophils were
calculated for FITC fluorescence (Figure 1a, b).
First, a ‘training set’ of 70 ANCA positive samples
with distinct ANCA specificities (anti-MPO-ANCA, n =
20 and anti-PR3-ANCA, n = 50) and 100 healthy con-
trols was used for the development and refinement of
pattern recognition algorithms for the new ANCA pat-
tern recognition algorithm module. The analysis of IIF
patterns by image-processing algorithms was separated
into two profiles for the recognition of ANCA IIF pat-
terns on ethN and formN. Furthermore, a differentiation
between positive and negative samples (quantitative
threshold values are given in Table 2) and additionally
between the two different basic ANCA IIF patterns
cytoplasmic and nuclear/perinuclear (Figure 1a, b) was
implemented. Five images per sample were taken auto-
matically. The images were focused employing the DAPI
fluorescence and the pattern recognition was performed
by adding FITC fluorescence signals of at least 20 neu-
trophils. Running the ‘training set’ samples, a 100% con-
sistency was achieved regarding positive/negative
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discrimination and determination of ANCA IIF patterns
by using the novel pattern recognition algorithms (data
not shown) in comparison to manual interpretation.
Signal variability of automated ANCA pattern
interpretation
In contrast to visual reading, measurement of quantita-
tive fluorescence signals for ANCA IIF pattern interpre-
tation provides for the first time the basis for objective
assay performance assessment by determination of assay
variability. Inter-assay coefficients of variation (CV) were
determined by running six ANCA positive samples with
differing ANCA titers in three different runs. The func-
tional assay sensitivity representing the lowest ANCA
concentration with a CV of lower than 20% was deter-
mined at a fluorescence intensity level of 40 AU for
ethN and 30 AU for formN (data not shown)
Positive/negative discrimination of ANCA by automated
interpretation
The established ANCA IIF pattern recognition algo-
rithm module was evaluated with the ‘test set’ compris-
ing 342 patient and control sera (Table 1) to assess the
ability to differentiate between positive and negative
formN
ethN
cytoplasmic     perinuclear      nuclear atypical atypical atypical
cytoplasmic  cytoplasmic negative      cytoplasmic     negative        negative
10 μm1a
A B1b
Figure 1 ANCA patterns and recognition thereof by mathematical algorithms. (a) Images (detail) of serum samples demonstrating C-ANCA,
P-ANCA, and atypical ANCA patterns on ethN and formN taken automatically by AKLIDES™. Chromatin is stained by DAPI (blue) and specific
ANCA interactions are revealed by FITC (green)-labeled secondary anti-human IgG. (b) Pattern recognition image of perinuclear (A) and
cytoplasmic (B) specific staining of neutrophils used by the novel algorithms for pattern differentiation: DAPI (blue) and FITC fluorescence
intensity signals (green) of respective images were combined and illustrated in three dimensions (x - object length, y - object width, light
intensity of fluorescence signal). C-ANCA, cytoplasmic antineutrophil cytoplasmic antibody; ethN, ethanol-fixed neutrophils; formN, formalin-fixed
neutrophils; P-ANCA, perinuclear antineutrophil cytoplasmic antibody.
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samples. To compare manual and automated positive/
negative discrimination, ANCA IIF patterns were inter-
preted automatically with AKLIDES™ followed by visual
interpretation with a routine fluorescence microscope
(Figure 1a). Appropriate ranges of quantitative fluores-
cence intensity data obtained with the ‘training set’ sam-
ples with AKLIDES™ were used to classify automated
findings into negative (-), borderline (+/-), weak positive
(+), positive (++), strong positive (+++), and very strong
positive (++++) (Table 2). The threshold values were
used for the positive/negative classification of the sam-
ples in the test set (Figure 2, Table 2).
Counting borderline samples as negative, the differ-
ences in positive and negative findings of 2.34% (95%
confidence interval (CI): -0.22 to 4.0%) on ethN and
0.58% (95% CI: -1.57 to 2.44%) on formN between both
interpretation methods were not significant according to
McNemar’s test (P = 0.0768, 0.7744, respectively).
Applying inter-rater agreement statistics for testing the
strength of agreement between two classifications,
Cohen’s kappa () values above 0.8 on ethN and formN
were obtained ( = 0.955, 95% CI: 0.944 to 0.965;  =
0.929, 95% CI: 0.895 to 0.964; respectively). Thus, visual
and automated interpretation revealed a very good
strength of agreement for the ‘test set’ sera.
ANCA IIF pattern recognition by automated interpretation
Employing the novel pattern recognition algorithms,
‘test set’ patient samples (n = 342) were interpreted
automatically with AKLIDES™ followed by visual inter-
pretation to compare the ANCA IIF pattern findings.
Four different patterns such as cytoplasmic, nuclear/
perinuclear, atypical, and negative were used to classify
automated and visual findings on ethN for inter-rater
agreement analysis (Table 3). Automated and visual
interpretation of ANCA pattern demonstrated a good
agreement with a  value of 0.746 on ethN (95% CI:
0.667 to 0.825). The main differences between visual
and automated interpretation for IIF patterns on ethN
were found for visual findings regarding cytoplasmic
and atypical patterns. Out of 88 cytoplasmic pattern
findings by visual interpretation, the automated reading
defined 22 (25.0%) as negative results. All these 22 IIF
images demonstrated a borderline cytoplasmic immuno-
fluorescence on AKLIDES™ that did not reach the
threshold for positivity used by the pattern recognition
algorithms. Nevertheless, there was no significant differ-
ence in the number of cytoplasmic patterns like for all
other patterns determined on ethN regarding automated
and visual interpretation (87/342 by visual vs. 62/342 by
automated interpretation, P = 1.00). Moreover, out of 55
atypical patterns determined visually, 10 (18.2%) were
defined as nuclear pattern using the automated pattern
recognition algorithms.
Due to the impaired mobility of MPO during formalin
fixation of neutrophils, only three kinds of patterns were
classified on formN (cytoplasmic, atypical, and negative).
Comparison of automated and visual interpretation on
Table 2 Comparison of manual and automated positive/negative discrimination assessing fluorescence intensity of
342 samples on ethN and formN patterns.
ethN Automated interpretation by AKLIDES™
n (%) - +/- + ++ +++ ++++
- 133 (38.9) 1 (0.3) 0 (0) 0 (0) 0 (0) 0 (0)
+/- 24 (7.0) 29 (8.5) 12 (3.5) 0 (0) 0 (0) 0 (0)
+ 0 (0) 4 (1.2) 44 (12.9) 11 (3.2) 0 (0) 0 (0)
++ 0 (0) 0 (0) 4 (1.2) 34 (9.9) 9 (2.6) 0 (0)
+++ 0 (0) 0 (0) 0 (0) 3 (0.9) 16 (4.6) 5 (1.5)
++++ 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 13 (3.8)
Visual interpretation formN
n (%) - +/- + ++ +++ ++++
- 225 (65.8) 8 (2.3) 2 (0.6) 2 (0.6) 0 (0) 0 (0)
+/- 9 (2.6) 22 (6.4) 5 (1.5) 0 (0) 0 (0) 0 (0)
+ 0 (0) 5 (1.5) 25 (7.3) 6 (1.7) 0 (0) 0 (0)
++ 0 (0) 0 (0) 2 (0.6) 20 (5.8) 1 (0.3) 0 (0)
+++ 0 (0) 0 (0) 0 (0) 1 (0.3) 6 (1.7) 0 (0)
++++ 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (0.9)
ANCA IIF patterns were first interpreted automatically with AKLIDES™ followed by manual reading with a routine fluorescence microscope. Both interpretation
methods demonstrated very good agreement on ethN and formN ( = 0.955, 95% confidence interval (CI): 0.944 to 0.965;  = 0.929, 95% CI: 0.895 to 0.964;
respectively). Quantitative fluorescence intensity threshold values for ethN: < 15 negative (-); ≥ 15 borderline (+/-) < 40; ≥ 40 weak positive (+) < 150; ≥ 150
positive (++) < 400; ≥ 400 strong positive (+++) < 700; ≥ 700 very strong positive (++++). Quantitative fluorescence intensity threshold values for formN: < 20
negative (-); ≥ 20 borderline (+/-) < 30; ≥ 30 weak positive (+) < 100; ≥ 100 positive (++) < 300; ≥ 300 strong positive (+++) < 600; ≥ 600 very strong positive (+
+++). ANCA, antineutrophil cytoplasmic antibody; ethN, ethanol-fixed neutrophils; formN, formalin-fixed neutrophils; IIF, indirect immunofluorescence.
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formN revealed a very good agreement ( = 0.847, 95%
CI: 0.790 to 0,904). Out of 100 cytoplasmic pattern find-
ings by visual interpretation, the automated reading
defined nine (9.0%) as negative results. These nine IIF
images demonstrated also a borderline cytoplasmic
immunofluorescence that did not reach the threshold
for positivity used by the pattern recognition algorithms.
In contrast, out of 234 negative samples by visual inter-
pretation, nine (3.8%) IIF pattern images were inter-









































Figure 2 Fluorescence intensity (AU) obtained by automated reading of AKLIDES™ compared to visual interpretation of ANCA IIF
pattern images on ethN (A) and formN (B) investigating serum samples of the ‘test set’. ANCA, antineutrophil cytoplasmic antibody; ethN,
ethanol-fixed neutrophils; formN, formalin-fixed neutrophils; IIF, indirect immunofluorescence.
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by visual interpretation were classified as cytoplasmic
pattern by automated interpretation, which was the only
significant difference between both methods for pattern
recognition on formN (P = 0.0075).
ANCA IIF pattern recognition comparison in different
clinical entities
Automated and visual interpretation of ANCA IIF pat-
terns on ethN and formN included different patient and
control group samples (Figure 3). Investigating sera
from patients with GPA (generalized and localized with
active and inactive disease state), EGPA (active and
inactive), MPA, SLE, RA, rheumatoid vasculitis, cryoglo-
bulinaemic vasculitis, systemic sclerosis, infectious dis-
ease and healthy controls, no significant difference
between both interpretation methods was established for
the respective clinical entities and controls (P > 0.05,
respectively).
Discussion
Testing for ANCA plays a pivotal role in the serological
diagnosis of AAV [22]. In accordance with international
guidelines, IIF and independent detection techniques
like ELISA should be used for the assessment of ANCA
[4,23]. Interestingly, IIF has been reported to be used as
a screening method due to its high sensitivity followed
by anti-PR3-ANCA and anti-MPO-ANCA ELISAs as
confirmatory tests under routine laboratory conditions
due to its high sensitivity and negative predictive value
[24]. In contrast to the ELISA technique, IIF is prone to
human bias and ANCA IIF image interpretation has
been not automated until recently [16]. Thus, the
recommended combination of IIF and confirmatory test-
ing requires a high level of expert knowledge and lacks
standardization [25]. Several studies tried to demon-
strate that ELISA technology is better adaptable for
standardization of ANCA assessment and has a lower
lab-to-lab variability compared to IIF [26-28]. However,
most commercially available ELISAs have been reported
to be inferior to IIF in terms of sensitivity [29]. There-
fore, automated interpretation of ANCA IIF patterns as
demonstrated for ANA detection by novel pattern
recognition algorithms could provide a cost-efficient and
standardized alternative approach for ANCA screening
[13-16]. In particular, regarding routine laboratories
with large numbers of ANCA determinations, auto-
mated interpretation would overcome shortcomings of
IIF such as high level of manual work and exceeding
data management [13,16].
Several studies have confirmed the usefulness of auto-
mated IIF systems for objective ANA pattern interpreta-
tions recently, providing the basis for the employment
of IIF as gold standard for ANA testing as required by
the American College of Rheumatology even under dif-
fering routine conditions [13,14,16,30].
In contrast to ANA detection on HEp-2 cells, poly-
morphonuclear granulocytes are characterized by vary-
ing shapes of the nucleus, which is usually lobed into
three segments. Therefore, algorithms for identification
of granulocyte staining patterns proved to be more com-
plex compared to those for HEp-2 cells. Furthermore,
ethN and formN show different boundary characteristics
with DAPI staining. Consequently, the type of fixation
needs to be taken into account assessing signal intensity
and pattern classification to adapt the algorithms to the
changed morphology.
Due to polymorphic nucleus and cytoplasmic ANCA
staining patterns, signal assessment and pattern classifi-
cation cannot be performed simply inside or outside of
the DAPI positive area as described for ANA pattern
detection [12,21]. Cytoplasmic and perinuclear ANCA
patterns need to be detected and identified in border
regions of the nucleus, rendering detection of ANCA
more complex and challenging for automation.
As a fact, our study did not establish a significant dif-
ference between automated and visual ANCA IIF detec-
tion investigating patients with AAV and disease
controls. Furthermore, the positive/negative discrimina-
tion and ANCA pattern assessment demonstrated a very
good agreement for ethN and formN, confirming the
usefulness of pattern recognition algorithms for the
automated interpretation of IIF patterns. In contrast to
the work of Melegari et al. reporting a very good consis-
tency for positive/negative discrimination by automated
Table 3 Comparison of visual and automated
interpretation of IIF ANCA patterns of the ‘test set’
patients (n = 342) on ethN and formN.
ethN Automated interpretation by AKLIDES™
n (%) cytoplasmic nuclear atypical negative
cytoplasmic 59 (17.2) 0 (0) 7 (2.0) 22 (6.4)
nuclear 0 (0) 61
(17.8)
4 (1.2) 0 (0)
atypical 3 (0.9) 10 (2.9) 40 (11.7) 2 (0.6)





n (%) cytoplasmic atypical negative
cytoplasmic 91 (26.6) 0 (0) 9 (2.6)
atypical 8 (2.3) 0 (0) 0 (0)
negative 9 (2.6) 0 (0) 225
(65.8)
ANCA IIF patterns were first read automatically with AKLIDES™ followed by
manual interpretation with a routine fluorescence microscope. Both
interpretation methods demonstrated good agreement on ethN and formN (
= 0.746, 95% CI: 0.667 to 0.825;  = 0.847, 95% CI: 0.79 to 0,904; respectively).
ANCA, antineutrophil cytoplasmic antibody; ethN, ethanol-fixed neutrophils;
formN, formalin-fixed neutrophils; IIF, indirect immunofluorescence.
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Figure 3 Comparison of automated and visual interpretation of ANCA IIF patterns in patient and control samples of the ‘test set’ on
ethN (A) and formN (B). Patterns of ethN and formN were first detected automatically by AKLIDES™ and then interpreted manually by a
routine fluorescence microscope. GPA, granulomatosis with polyangiitis (Wegener’s) (n = 59); EGPA, eosinophilic granulomatosis with polyangiitis
(Churg-Strauss Syndrome) (n = 40); MPA, microscopic polyangiitis (n = 20); SLE, systemic lupus erythematosus (n = 40); RA, rheumatoid arthritis
(n = 30); RA RV, rheumatoid arthritis with rheumatoid vasculitis (n = 10); Cr V, cryoglobulinaemic vasculitis (n = 10); HC, healthy control (n = 44);
S Scl, systemic sclerosis (n = 38), Inf dis, infectious disease (n = 51).
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and visual interpretation in a review, in this study
ANCA patterns were also analyzed on neutrophils with
two different fixation methods.
Moreover, this is the first study on ANCA IIF pattern
reading, reporting quantitative data for interassay varia-
bility. As shown for anti-dsDNA and ANA detection by
IIF recently, this approach allows determining a func-
tional assay sensitivity giving the lowest fluorescence
intensity with an interassay variability of equal or less
than 20% [15,31,32]. This creates the opportunity for a
standardized cutoff determination improving the test
accuracy for borderline samples and might provide a
better reporting of ANCA IIF results to clinicians in
order to support the progress in the treatment of AAV
[33]. Relying on quantitative data for ANCA IIF reading
may even give the opportunity to report findings for dif-
ferent test-result intervals as proposed recently for
ANCA testing by ELISA [34].
Conclusions
Novel ANCA pattern recognition algorithms are a very
useful tool for the automated reading of ANCA patterns
on ethN and formN and can further improve the stan-
dardization efforts for the detection of ANCA. The
automated evaluation is prone to render the comparison
of diagnostic data possible. This is most important for
clinical studies but also for diagnostic purposes and in
clinical research. Automated pattern interpretation
demonstrated high diagnostic performance for the
assessment of ANCA and revealed no difference to
visual reading. Further studies are warranted to evaluate
this novel fully automated approach for automated soft-
ware-based screening of ANCA in patients with sus-
pected AAV.
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